Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MAZE

Maze Therapeutics Inc

Mar 14 • 04:00PM ET

10.99

Dollar change -0.31
Percentage change -2.74	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	46.06%	Shs Outstand	43.78M	Perf Week	-8.42%
Market Cap	481.11M	Forward P/E	-	EPS next Y	-2.65	Insider Trans	0.00%	Shs Float	23.61M	Perf Month	-8.26%
Income	-	PEG	-	EPS next Q	-0.71	Inst Own	12.59%	Short Float	7.10%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-8.55%	Inst Trans	-99.77%	Short Ratio	5.48	Perf Half Y	-
Book/sh	-6.50	P/B	-	EPS next Y	-4.33%	ROA	-	Short Interest	1.68M	Perf Year	-
Cash/sh	3.42	P/C	3.22	EPS next 5Y	-6.79%	ROE	-	52W Range	10.08 - 17.00	Perf YTD	-31.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-35.35%	Beta	-
Dividend TTM	-	Quick Ratio	8.77	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.03%	ATR (14)	1.34
Dividend Ex-Date	-	Current Ratio	8.77	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	34.62	Volatility	9.74% 12.24%
Employees	-	Debt/Eq	0.80	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	25.67
Option/Short	No / Yes	LT Debt/Eq	0.75	EPS Q/Q	-	Payout	-	Rel Volume	0.37	Prev Close	11.30
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	305.67K	Price	10.99
SMA20	-6.36%	SMA50	-10.13%	SMA200	-10.13%	Trades		Volume	113,262	Change	-2.74%

Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Loading…
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAZE

Maze Therapeutics Inc

Upgrade your FINVIZ experience